Evidence map›Paper›PMID 25485152›Full record

ReviewSchizophrenia research and treatment2014

Eating disorders in schizophrenia: implications for research and management.

Youssef Kouidrat, Ali Amad, Jean-Daniel Lalau, Gwenole Loas

Open access · hybridAbstract readReview
In one paragraph

Review in Schizophrenia research and treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 5 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 5 syntheses or guidelines pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Associations between Schizotypal Facets and Symptoms of Disordered Eating in Women.International journal of environmental research and public health · 2022
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Youssef KouidratDepartment of Endocrinology, University of Picardie-Jules Verne, CHU d'Amiens, Amiens, France ; Department of Nutrition, Hôpital maritime, Assistance Publique-Hôpitaux de Paris (AP-HP), 62600 Berck, France.ORCID 0000-0002-4188-1428
Ali AmadPsychiatry Department and SCA-lab, PSYchiC team, Université de Lille, 59100 Lille, France.ORCID 0000-0002-9029-2910
Jean-Daniel LalauDepartment of Endocrinology, University of Picardie-Jules Verne, CHU d'Amiens, Amiens, France.ORCID 0000-0001-7167-9872
Gwenole LoasDepartment of Psychiatry, Erasme Hospital, ULB, 1070 Brussels, Belgium.
Assistance Publique – Hôpitaux de Paris · FRErasmus Hospital · BEUniversité de Lille · FRUniversité de Picardie Jules Verne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective. Despite evidence from case series, the comorbidity of eating disorders (EDs) with schizophrenia is poorly understood. This review aimed to assess the epidemiological and clinical characteristics of EDs in schizophrenia patients and to examine whether the management of EDs can be improved. Methods. A qualitative review of the published literature was performed using the following terms: "schizophrenia" in association with "eating disorders," "anorexia nervosa," "bulimia nervosa," "binge eating disorder," or "night eating syndrome." Results. According to our literature review, there is a high prevalence of comorbidity between schizophrenia and EDs. EDs may occur together with or independent of psychotic symptoms in these patients. Binge eating disorders and night eating syndromes are frequently found in patients with schizophrenia, with a prevalence of approximately 10%. Anorexia nervosa seems to affect between 1 and 4% of schizophrenia patients. Psychopathological and neurobiological mechanisms, including effects of antipsychotic drugs, should be more extensively explored. Conclusions. The comorbidity of EDs in schizophrenia remains relatively unexplored. The clearest message of this review is the importance of screening for and assessment of comorbid EDs in schizophrenia patients. The management of EDs in schizophrenia requires a multidisciplinary approach to attain maximized health outcomes. For clinical practice, we propose some recommendations regarding patient-centered care.

Identifiers

PMID25485152
PMCPMC4251071
OpenAlexW2137790859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.